Wow, this is a big moment for the stem cell community. We officially crossed 300,000 stem cell publications released to PubMed.gov. PubMed is a service of the U.S. National Library of Medicine and NIH that comprises more than 27 million citations for biomedical literature. It is the largest and comprehensive global database that exists for scientific publications. [Read more…]
Recently, we released an article stating that two-thirds of mesenchymal stem cell (MSC) scientific publications were released in the past 5 years, even though there is a 40 year history of MSC publications.
What is even more shocking is that more than a quarter (27.4%) of all MSC publications were released during 2014 or 2015, the previous two years.
Moreover, 2016 data shows that we are on track for a nearly 20% increase in MSC publications over 2015.
At BioInformant, we have been tracking the mesenchymal stem cell market for a full decade (2006 to present) and we have never seen MSC scientific publication data look like this.
In market research, we are at what we call an “Inflection Point.” Meaning, we are at a time of significant change in a situation, a turning point.
Whether you manufacture stem cell products, develop stem cell therapies, or offer cord blood banking services, you need to be aware of trends like this.
Explore our blog for more free content on mesenchymal stem cell (MSC) market trends or check out the global strategic report “Mesenchymal Stem Cells – Advances & Applications.”
*Note: PubMed search of terms “mesenchymal stem cell” and “mesenchymal stem cells” executed July 15, 2016.
BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.